Edasalonexent clinical trials
Also written CAT-1004.
How each study uses edasalonexent is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2012 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses edasalonexent is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Phase 1/2 Study in Boys With Duchenne Muscular DystrophyCompletedPhase 1/2Catabasis PharmaceuticalsNCT02439216Written as Edasalonexent
- Phase III Study of Edasalonexent in Boys With Duchenne Muscular DystrophyCompletedPhase 3Catabasis PharmaceuticalsNCT03703882Written as Edasalonexent
- An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular DystrophyTerminatedPhase 3Catabasis PharmaceuticalsNCT03917719Written as Edasalonexent
- A Study of CAT-1004 Biomarkers in Healthy SubjectsCompletedPhase 1Catabasis PharmaceuticalsNCT01670773Written as CAT-1004
- A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 DiabetesCompletedPhase 1Catabasis PharmaceuticalsNCT01511900Written as CAT 1004
- Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult VolunteersCompletedPhase 1Catabasis PharmaceuticalsNCT01440166Written as Drug
Given beside what is tested · 1 — edasalonexent is usual care or a partner of the new treatment
Codes
What other systems call edasalonexent · ClinicalTrials.gg INT000768
- UNII (FDA) AF3Z6434KSEDASALONEXENTConfirmed FDA, Wikidata
- Wikidata Q27273902edasalonexentConfirmed FDA, Wikidata
- NCI Thesaurus C171665EdasalonexentOne source FDA
- DrugBank DB15010One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | AF3Z6434KS | EDASALONEXENT | Confirmed FDA, Wikidata |
| Wikidata | Q27273902 | edasalonexent | Confirmed FDA, Wikidata |
| NCI Thesaurus | C171665 | Edasalonexent | One source FDA |
| DrugBank | DB15010 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.